Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SB17170 in Healthy Adults
NCT05795192Phase 1Completed
- Sponsor
- SPARK Biopharma
- Start
- May 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SB17170 in solid tumor and idiopathic pulmonary fibrosis (IPF) (18 arms), sponsored by SPARK Biopharma. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started May 2023; status: completed.
02
Drugs
SB17170
03
Conditions
solid tumoridiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05795192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795192.